How to read: Every bubble is one Indian glucosamine exporter. X-axis = shipment count; Y-axis = average unit price; bubble size = total revenue. Dashed lines split at the median — exporters in the top-right (Bulk Leaders) combine high volume with premium pricing.
HOW TO READ THIS REPORT
60 seconds
Scan this page — KPIs, thesis, flagship chart, top findings
5 minutes
Read every Key Takeaway line across §1–§9
30 minutes
Read sections tagged for your role ([S] or [B]) end-to-end
In depth
Drill into §10 for your country · supplier / buyer directories at end
02
PART I — OVERVIEW
About This Report
Data sources, methodology, trust signals, and what this Glucosamine report covers
KEY TAKEAWAYEvery figure in this report is grounded in real commercial glucosamine trade records. Data comes from official customs filings and public trade sources, runs through a multi-layer quality process, and lands in a clean, consistent report you can rely on.
S FOR SUPPLIERS
Every competitor benchmark, market share figure, and buyer list in this report comes from verified commercial shipments — not surveys or estimates. Use them with confidence when planning your next pitch.
B FOR BUYERS
Every supplier profile, price benchmark, and trade route in this report reflects what that supplier actually ships — real volumes, real destinations, real prices. Use them to qualify and compare Indian glucosamine suppliers.
§2.1 Reporting parameters · the scope of this 2025-Q4 Glucosamine India trade report
P
Product scope
Glucosamine
All variants merged — branded and generic formulations of glucosamine
T
Time period
2025-Q4
October, November, December 2025 — a single-quarter snapshot
S
Data sources
Official & public trade records
Government customs filings, public trade databases and licensed commercial feeds
G
Geography
India origin → global
Indian sea and air ports shipping to destination markets worldwide
C
Currency
USD (FOB)
Declared Free-on-Board value at the Indian port of loading
R
Shipments analysed
48
Every commercial glucosamine trade record in the period, aggregated and deduplicated
§2.2 Our quality process · Figure 2.1
Figure 2.1 From raw trade records to a clean report — the four quality pillars.
How to read: Raw trade data (left) flows through four quality checks — source verification, format standardisation, entity matching, and deduplication — to produce the clean, reliable data (right) behind every chart and table in this report.
§2.3 Trust signals · what you can rely on in the numbers you read
DATA COVERAGE
10M+
Pharmaceutical trade records across the full TransData Nexus platform.
COUNTRIES
150+
Origin and destination countries covered in the global pharma trade database.
Platform refresh cadence. This report is a snapshot from the same live data.
§2.4 Limitations · what the data does and does not tell you
WHAT THIS DATA DOES AND DOES NOT SAY
Prices are at the Indian port of loading (FOB), not the final delivered cost in the destination country. Freight, insurance, import duty and local margin are not included.
This is a single-quarter snapshot. Multi-quarter trends, year-over-year growth and historical comparisons are available on the full platform.
A small number of records have incomplete transport mode or destination port fields; these appear blank in the shipment register but are still counted in totals.
This report is a commercial intelligence tool, not a legal audit. For high-stakes decisions, cross-reference with the underlying trade records via the full platform.
03
PART II — MARKET STRUCTURE
Quarterly Trade Overview
Monthly trends, regional performance, and ranking shifts — 2025-Q4
KEY TAKEAWAY2025-Q4 followed a steady rise: Oct $142.4K, Nov $159.9K, Dec $389.8K. Shipment counts rose across the quarter.
S FOR SUPPLIERS
Track which months your competitors were most active, which destinations rose or fell, and whether the Nov dip hit your segment. The bump charts show rank movement — watch for rivals climbing past you.
B FOR BUYERS
Identify whether your current Indian supplier maintained steady shipments through the quarter, or whether they pulled back. Steady suppliers during dips signal reliable partnerships.
1
$142.4K
Oct USD
9 shipments
2
$159.9K
Nov USD
+12.2% MoM
3
$389.8K
Dec USD
+143.8% MoM
4
Steady rise
Q4 growth shape
Oct → Nov → Dec
Fig 3.1 Nov rose 12.2% in USD but shipment count kept climbing.
How to read: Blue bars = monthly USD. Orange line = shipment count. When bars drop but line rises, average shipment value fell. Insight: Oct opened at $142K, making it the weakest month by value.
How to read: The curve shows the running total across the quarter. A steeper slope means that month contributed more revenue. Insight: The curve’s steepest section reveals which month drove the most trade value.
How to read: Each coloured layer is one destination region. Layer height = USD in that month. Insight: The top region contributed the most, while the smallest region had the least volume.
How to read: Each line traces a supplier’s monthly rank. Flat = stable position; crossing = rank change. Insight: SAVA HEALTHCARE LTD maintained its leading position.
04
PART II — MARKET STRUCTURE
Global Destination Map
Which countries import glucosamine from India, how much they buy, and who supplies each market
KEY TAKEAWAYRomania absorbs 27.3% of India’s 2025-Q4 glucosamine trade ($189.1K). Beyond the top 10 destinations, 21 countries have fewer than 5 Indian suppliers each — white-space markets where new entrants face minimal competition. Africa has 9 destination countries, the widest regional diversity.
S FOR SUPPLIERS
Use the flow map and lanes table to see which destinations your competitors dominate. For small and mid-size suppliers: look beyond the leading markets — the 21 countries in the long tail have fewer than 5 Indian suppliers each and low competitive barriers.
B FOR BUYERS
Find your country on the map to see how much glucosamine India ships to your market, who the top suppliers are, and whether you’re in a concentrated or competitive corridor.
Asia
$102K
14.7% of trade
5 countries · 12 shipments
Europe
$438K
63.3% of trade
4 countries · 18 shipments
Americas
$75K
10.8% of trade
3 countries · 4 shipments
Africa
$78K
11.2% of trade
9 countries · 14 shipments
Fig 4.1 Romania is the #1 corridor ($189K) — 21 flow arcs from India radiate across 4 continents.
How to read: The world map shows every country colored by how much Indian glucosamine it receives (light = low, dark = high). Orange arcs radiate from India to the top 21 destinations; arc thickness = USD value. All destinations are labeled with country name + USD.
§4.1 Top 10 bilateral trade lanes (India → destination) with top Indian suppliers
#
Destination
Total USD
Ships
#1 Indian supplier
USD
#2 Indian supplier
USD
#3 Indian supplier
USD
1
Romania
$189K
7
SAVA HEALTHCARE LTD
$189K
—
—
—
—
2
France
$148K
4
TROIKAA PHARMACEUTICALS LTD
$133K
MEDNEXT BIOTECH LTD
$15K
—
—
3
Russia
$100K
3
PANACEA BIOTEC PHARMA LTD
$100K
—
—
—
—
4
Singapore
$67K
1
MEDREICH LTD
$67K
—
—
—
—
5
El Salvador
$46K
1
CAPLIN POINT LABORATORIES LTD
$46K
—
—
—
—
6
Nigeria
$43K
2
ASOJ SOFT CAPS PVT LTD
$43K
—
—
—
—
7
Ghana
$29K
1
THE MADRAS PHARMACEUTICALS
$29K
—
—
—
—
8
Guatemala
$27K
2
XL LABORATORIES PVT LTD
$27K
—
—
—
—
9
Kazakhstan
$18K
1
OXFORD LABORATORIES PVT LTD
$18K
—
—
—
—
10
Afghanistan
$10K
4
ANVIS LABORATORIES PVT LTD
$6K
ZEE LABORATORIES LTD
$4K
—
—
Table 4.1 — Top 10 destination countries ranked by trade value, with the largest Indian suppliers for each market.
Fig 4.2 Asia leads at 14.7% of USD — but Romania is the single largest market.
How to read: Column width = region USD share. Within each column, cells are stacked by country, height = share within region.
§4.2 Destination concentration
27.3%
#1 country share
Romania alone
79.4%
Top 5 share
5 of 21 countries
99.8%
Top 15 share
Long tail of 6 countries = 0.2%
HHI 1631
Destination HHI
Moderately concentrated
21
Countries served
Global pharma reach from India
9
Africa countries
Widest regional diversity
Source: TransData Nexus trade data platform
05
PART III — WHO’S IN THIS MARKET
Indian Supplier Rankings & Profiles
24 Indian exporters ranked by value — profiles, portfolios, and competitive intelligence
KEY TAKEAWAYSAVA HEALTHCARE LTD ($190.3K, 27.5% share) and TROIKAA PHARMACEUTICALS LTD ($133.2K) together control 46.7% of India’s 2025-Q4 glucosamine trade. The top 5 suppliers hold 78.4%. 24 companies shipped at least once.
S FOR SUPPLIERS
Find your rank, your competitors’ ranks, and the gap in USD/share between you. The profile pages show each top supplier’s buyer portfolio, dosage mix and route map — your competitive-intelligence toolkit.
B FOR BUYERS
Find potential Indian glucosamine suppliers ranked by size, catalog breadth and destination reach. The profile pages reveal which suppliers have proven trade lanes to your region.
Fig 5.1 SAVA HEALTHCARE LTD leads by $57K over TROIKAA PHARMACEUTICALS LTD — top 20 Indian exporters ranked by trade value
How to read: Each bar = one Indian supplier ranked by USD. The (#N) shows their rank by shipment count — mismatches reveal pricing strategy. Insight: MERCURY MEDICARE is #20 by value but #11 by volume.
Fig 5.2 SAVA HEALTHCARE LTD also leads by shipment count (11) but ranking shifts for volume-heavy players
How to read: Same suppliers re-ranked by shipment count. The (#N) shows their rank by USD value. Insight: MERCURY MEDICARE moves from #11 by volume to #20 by value — fewer but higher-value shipments.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — Archetypes & Concentration
How India’s 24 glucosamine suppliers split into strategic segments
KEY TAKEAWAY6 suppliers (25%) generate 84.6% of total trade value. The market splits into four archetypes: Market Leaders, High-Value specialists, Volume players, and a long tail.
Fig 5.3 SAVA HEALTHCARE LTD and TROIKAA PHARMACEUTICALS LTD sit in the leaders zone — high volume AND high value.
How to read: Each bubble is one Indian supplier. X-axis = shipment count (log scale); Y-axis = total USD value (log scale); bubble size = revenue. Blue dashed lines split at the median. Market Leaders (top-right) combine high volume with high value. Premium Niche (top-left) ship fewer but higher-value consignments. Volume Players (bottom-right) compete on quantity. Long-Tail (bottom-left) are small or occasional exporters. Conclusion: the log scale reveals clear strategic clusters — use this map to identify where your company sits relative to competitors.
Fig 5.4 25% of suppliers = 84.6% of USD — classic concentration.
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 2 destinations and up to 1 importers per destination.
06
PART III — WHO’S IN THIS MARKET
Global Buyer Rankings & Intelligence
23 importers across 21 countries — who is buying Indian glucosamine and how much
KEY TAKEAWAYThe demand side is dramatically more fragmented than supply: the top 21 importers together hold only 74.5% of total USD. 91% of buyers source from a single Indian supplier — a vast pool of lock-in candidates.
S FOR SUPPLIERS
Find the importers buying from your competitors. The rankings reveal who has volume, who pays well, and who sources from multiple Indian suppliers (potential pitch targets).
B FOR BUYERS
See where you rank among global importers of Indian glucosamine. Compare your USD and shipment count against peers in your country and dosage segment.
Fig 6.1 MOVI HEALTH LLC is the #1 importer at $190K (27.5%) — top 21 by trade value
How to read: Left semicircle = top 20 Indian suppliers; right = top 20 global buyers. Arc length = total USD; colored ribbons = individual relationships, thickness = USD value. Insight: follow the thickest ribbons to identify the dominant trading pairs.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
How Indian glucosamine prices vary by supplier, country and dosage form
KEY TAKEAWAYGlucosamine prices span 48578× ($0.0006 → $29.70). The coefficient of variation is 1.54. Dosage form, not destination, is the primary price driver.
S FOR SUPPLIERS
Use the box plot to see where your product sits on the price spectrum. The tornado chart shows exactly where you sit relative to the market median.
B FOR BUYERS
Use this section to benchmark the price you pay against the market. The percentile strip tells you if your current supplier is charging you premium, mid-market or budget rates.
How to read: Each bar shows one supplier’s average unit price relative to the market median (dashed line). Red = above median (premium), green = below (budget).
COMMODITY KINGS
high volume · low unit price
Bulk API/tablet. Largest absolute USD despite lowest per-unit prices. e.g. PANACEA BIOTEC PHARMASourcing: best for cost-driven procurement.
BULK LEADERS
high volume · premium price
Branded-generic leaders, above-median pricing. e.g. SAVA HEALTHCARE LTDSourcing: hardest to displace; compete on relationship.
LONG-TAIL
low volume · low unit price
Spot/opportunistic players. e.g. CAPLIN POINT LABORATORIESSourcing: first to approach for new tenders.
PREMIUM NICHE
low volume · premium price
Sterile injectables and infusions. Hospital-grade. e.g. THE MADRAS PHARMACEUTICALSSourcing: expect 10× price vs tablet.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
Outlier forensics and the procurement cheat sheet — what to expect to pay by country × dosage
KEY TAKEAWAYExtreme prices are real: the highest are specialty/sterile formulations; the lowest are bulk API. The cheat sheet matrix is the take-home reference for procurement teams.
§7.2 Outlier forensics — top 10 highest and 10 lowest unit prices
↑ TOP 10 HIGHEST USD/UNIT
Date
Exporter
Country
Dosage
Qty
USD
$/unit
Why
Nov 2025
REGAL LABORATORIES
Equatorial Guinea
Tablet
45
$1K
$29.70
Specialty / small-batch
Dec 2025
MEDREICH LTD
Singapore
Capsule
5K
$67K
$13.71
Specialty / small-batch
Dec 2025
SAVA HEALTHCARE …
Romania
Tablet
5K
$45K
$9.72
Specialty / small-batch
Dec 2025
SAVA HEALTHCARE …
Romania
Tablet
2K
$19K
$8.09
Specialty / small-batch
Oct 2025
MEDNEXT BIOTECH …
France
Tablet
3K
$15K
$5.23
Specialty / small-batch
Nov 2025
COMED CHEMICALS …
Kenya
Tablet
610
$3K
$5.23
Specialty / small-batch
Dec 2025
SAVA HEALTHCARE …
Romania
Tablet
9K
$43K
$4.76
Specialty / small-batch
Dec 2025
SAVA HEALTHCARE …
Ukraine
Tablet
120
$571.57
$4.76
Specialty / small-batch
Oct 2025
SAVA HEALTHCARE …
Romania
Tablet
4K
$21K
$4.63
Specialty / small-batch
Dec 2025
SAVA HEALTHCARE …
Romania
Tablet
5K
$19K
$4.08
Specialty / small-batch
↓ TOP 10 LOWEST USD/UNIT
Date
Exporter
Country
Dosage
Qty
USD
$/unit
Why
Dec 2025
VEA IMPEX (I) PV…
Seychelles
Tablet
100
$1.52
$0.015
Small sample / trial shipment
Dec 2025
DISTINCT IMPEX P…
Iraq
Tablet
1K
$15.60
$0.016
Dec 2025
DISTINCT IMPEX P…
Iraq
Tablet
1K
$15.60
$0.016
Dec 2025
AL-SUPREME EXPORTS
Seychelles
Tablet
60
$1.91
$0.032
Small sample / trial shipment
Nov 2025
PANACEA BIOTEC P…
Russia
Capsule
665K
$32K
$0.049
Dec 2025
PANACEA BIOTEC P…
Russia
Capsule
1.3M
$67K
$0.050
Bulk volume discount
Nov 2025
CAPLIN POINT LAB…
El Salvador
Tablet
768K
$46K
$0.060
Nov 2025
BAKER & DAVIS PV…
Chad
Tablet
1K
$109.81
$0.110
Nov 2025
BAKER & DAVIS PV…
Chad
Tablet
1K
$109.81
$0.110
Nov 2025
RUSHI MARKETING
DR Congo
—
200
$36.86
$0.184
Small sample / trial shipment
§7.3 Procurement cheat sheet — median USD/unit by country × dosage
Fig 7.2 Median unit price by country × dosage form — darker cells = higher prices.
How to read: Each cell shows the median price per unit for that country-dosage combination. Dark blue = expensive, light = cheap. Blank cells = no shipments in that combination.
NEGOTIATION RANGE
Use each cell value as the anchor price. Typical dynamics:
Dosage form is the #1 price driver, not destination
Light cells = easy-entry markets for small suppliers
Dark cells = premium markets requiring regulatory investment
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Which Indian ports ship glucosamine, which global ports receive it, and which corridors are high-value vs bulk
KEY TAKEAWAYGlucosamine leaves India through 16+ ports. The top 5 (MUNDRA SEA, AHMEDABAD ICD, DELHI AIR) handle 83.5% of total USD. SEA moves 31% of shipments.
S FOR SUPPLIERS
Use the dumbbell to classify your port as high-value hub or bulk workhorse. Note the short-sea routes — Bangladesh, Sri Lanka, Myanmar and East Africa are the easiest logistics corridors for first-time exporters.
B FOR BUYERS
Use the destination port ranking to find which Indian ports serve your market. The lead-time estimates tell you what transit time to expect.
Fig 8.1 MUNDRA SEA handles $232K — top 16 Indian origin ports by trade value.
How to read: Each bar = one destination port worldwide. Bar length = USD value received from India.
§8.1 Reference transit times for key India → global corridors
Route
Mode
Transit time
Notes
NHAVA SHEVA SEA (JNPT) → US East Coast
Sea
22–28 days
Via Suez; 2–3 transshipments typical
NHAVA SHEVA SEA (JNPT) → Lagos (Nigeria)
Sea
18–24 days
Direct liner service available
MUMBAI AIR (SAHAR) → New York JFK
Air
3–5 days
Direct cargo; cold-chain available
MUNDRA SEA → Rotterdam
Sea
20–26 days
Via Suez; Hamburg also served
HYDERABAD AIR → London Heathrow
Air
2–4 days
Pharma-grade cargo corridor
CHENNAI SEA → Chittagong (Bangladesh)
Sea
7–12 days
Short-sea route; high frequency
RAXAUL → Birgunj (Nepal)
Road
1–2 days
Land border crossing
NHAVA SHEVA SEA (JNPT) → Mombasa (Kenya)
Sea
14–20 days
Direct or via Colombo hub
Table 8.1 — Reference times based on standard shipping corridors. Air = 2–5 days; sea = 7–28 days; road = 1–2 days. Add 3–7 days for customs clearance at destination.
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Trade corridors — origin port to mode of transport to destination region
KEY TAKEAWAYSEA dominates at 31% of shipments. The alluvial traces every dollar from Indian origin port through transport mode to destination region.
SEA
$323K
46.6% of USD · 31.3% of ships
ICD
$240K
34.7% of USD · 25.0% of ships
AIR
$129K
18.7% of USD · 43.8% of ships
Fig 8.3 The dominant corridor is MUNDRA SEA → Sea → Europe ($189K).
How to read: Left = Indian origin ports. Middle = transport mode. Right = destination region. Ribbon thickness = USD value; color = mode. Follow the thickest ribbons to find the highest-value corridors.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market concentration, supply-chain risk, and the dependency patterns that signal where to act
KEY TAKEAWAYRomania is the most concentrated destination (HHI 10000, 1 suppliers). Afghanistan is the most competitive (HHI 5131).
S FOR SUPPLIERS
The HHI barbell shows where competitors have locked up a market (concentrated = poaching opportunity) vs where you must compete on quality (fragmented). The slope chart reveals who is gaining ground.
B FOR BUYERS
The HHI barbell tells you whether your country has enough supplier options. If concentrated (red zone), you have fewer alternatives.
Fig 9.1 Romania (HHI 10,000) is the most concentrated — Afghanistan (HHI 5,131) is the most competitive.
What is HHI? The Herfindahl-Hirschman Index measures how concentrated a market is among its suppliers. It ranges from 0 to 10,000. Below 1,500 (green zone) = many suppliers compete openly — healthy, competitive market with low risk. 1,500–2,500 (yellow zone) = a few suppliers hold significant share — moderate concentration. Above 2,500 (red zone) = one or two suppliers dominate the market — high risk for buyers who may lose supply, and hard to break into for new suppliers. Conclusion: 20 of 20 destination markets are concentrated (red zone). 0 are competitive (green zone). Buyers in red-zone markets should urgently qualify a second Indian supplier to reduce dependency risk.
§9.1 Single-source dependencies
Buyer
Country
Sole supplier
USD
Ships
Risk
MOVI HEALTH LLC
Romania
SAVA HEALTHCARE …
$190K
11
HIGH
PANBIO PHARM LLC
Russia
PANACEA BIOTEC P…
$100K
3
MEDIUM
PHARMAZEN MEDICALS P…
Singapore
MEDREICH LTD
$67K
1
MEDIUM
DROGUERIA SAIMED S.A…
El Salvador
CAPLIN POINT LAB…
$46K
1
MEDIUM
LYMENS MEDICAL SUPPL…
Ghana
THE MADRAS PHARM…
$29K
1
MEDIUM
FUTURA, SOCIEDAD ANO…
Guatemala
XL LABORATORIES …
$27K
2
MEDIUM
TOO ANADHI
Kazakhstan
OXFORD LABORATOR…
$18K
1
MEDIUM
EURIMEX PHARMAPARC D…
France
MEDNEXT BIOTECH …
$15K
1
MEDIUM
Conclusion: 21 buyers depend on exactly one Indian supplier, representing $516K in trade. For suppliers: each row is a competitor’s locked-in customer you can target.
§9.2 Multi-source resilience
Buyer
Country
Suppliers
USD
Dominant
Resilience
Conclusion: 0 of these buyers have HIGH resilience (3+ active suppliers). These are the hardest accounts to win but safest partners for long-term contracts.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market entry playbook and risk landscape by destination country
KEY TAKEAWAY15 target markets with specific entry approaches. Large suppliers: focus on regulated Tier 1 markets. Small/mid-size: start with Tier 2–3 (low barrier, growing demand).
§9.3 Sourcing recommendations · Table 9.1
Country
Tier
Lead
Price
Risk
Entry approach
Romania
Tier 3 (emerging)
14–28 days (sea)
$1–$10/unit
LOW
First-mover advantage
France
Tier 3 (emerging)
14–28 days (sea)
$1–$10/unit
LOW
First-mover advantage
Russia
Tier 3 (emerging)
3–5 days (air)
$0.01–$0.10/unit
LOW
First-mover advantage
Singapore
Tier 3 (emerging)
14–28 days (sea)
$1–$10/unit
LOW
First-mover advantage
El Salvador
Tier 3 (emerging)
14–28 days (sea)
$0.01–$0.10/unit
LOW
First-mover advantage
Nigeria
Tier 3 (emerging)
14–28 days (sea)
$1–$10/unit
LOW
First-mover advantage
Ghana
Tier 3 (emerging)
14–28 days (sea)
$1–$10/unit
LOW
First-mover advantage
Guatemala
Tier 3 (emerging)
14–28 days (sea)
$1–$10/unit
LOW
First-mover advantage
Kazakhstan
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Afghanistan
Tier 3 (emerging)
14–28 days (sea)
$0.10–$1/unit
LOW
First-mover advantage
Malaysia
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Kenya
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Equatorial Guinea
Tier 3 (emerging)
14–28 days (sea)
$1–$10/unit
LOW
First-mover advantage
Ukraine
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Haiti
Tier 3 (emerging)
14–28 days (sea)
$1–$10/unit
LOW
First-mover advantage
For suppliers: Tier 1 markets (US, UK, France) require regulatory investment but offer premium pricing. Tier 3 markets (emerging) have low barriers — ideal for first-time exporters. For buyers: Use the price band and lead time to benchmark your current supplier’s terms.
Fig 9.2 0 markets in the Growth Opportunity zone (competitive + growing). 12 in Fragile Dependency (concentrated + shrinking).
How to read: Each bubble = one destination. X-axis = HHI (concentration). Y-axis = growth %. Bubble size = USD. Green zone (top-left) = Growth Opportunity — competitive markets that are growing, best for new entrants. Red zone (bottom-right) = Fragile Dependency — concentrated + shrinking, high supply-chain risk. Conclusion: Key markets are the top growth opportunities.
09
PART V — ACTION
Action Plan & Easy-Entry Markets
12 prioritised actions + 15 low-competition destination countries for small & mid-size suppliers
KEY TAKEAWAYQuick Wins: execute this quarter. Big Bets: plan for next 6–12 months. Plus 15 countries with ≤5 Indian suppliers — the best entry points for SMEs.
S
FOR SUPPLIERS
ID
Action
Timing
Impact
A1
Pitch top single-source buyer in Romania
This Q
HIGH
A2
Offer alternative to top multi-source buyer
This Q
HIGH
A3
Audit Romania lock-ins (HHI 10000)
This Q
MED
A5
Enter Malaysia (3 suppliers)
This Q
HIGH
A6
Enter Romania (1 suppliers)
This Q
MED
A8
Build France distribution
6–12m
HIGH
A9
Bundle injection/infusion catalog for premium markets
6–12m
MED
B
FOR BUYERS
ID
Action
Timing
Impact
A4
Monitor rising exporters (climbers)
This Q
MED
A7
Register for Romania tenders
6–12m
HIGH
A10
Track quarterly HHI shifts across key destinations
This Q
LOW
A11
Map competitor buyer portfolios quarterly
This Q
MED
A12
Qualify second source for single-source buyers
This Q
MED
§9.4 Easy-entry markets — 15 countries with ≤5 Indian suppliers
#
Country
Region
Suppliers
Q4 USD
Growth
Barrier
Why this is easy
1
Malaysia
Asia
3
$7K
+23364.3%
LOW
Growing 23364% with only 3 competitors
2
Romania
Other
1
$189K
+709.1%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
3
France
Other
2
$148K
-100%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
4
Russia
Other
1
$100K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
5
Singapore
Asia
1
$67K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
6
El Salvador
Other
1
$46K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
7
Nigeria
Africa
1
$43K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
8
Ghana
Africa
1
$29K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
9
Guatemala
Other
1
$27K
-100%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
10
Kazakhstan
Asia
1
$18K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
11
Afghanistan
Asia
2
$10K
+38.7%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
12
Kenya
Africa
1
$3K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
13
Equatorial Guinea
Africa
1
$1K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
14
Ukraine
Other
1
$1K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
15
Haiti
Other
1
$1K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
This report covers 48 2025-Q4 Glucosamine shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/glucosamine
10
PART VI — EVIDENCE REGISTER
Comprehensive Shipment Records by Region
Authoritative source behind all analytics in this report — every shipment appears exactly once
KEY TAKEAWAYThis section contains every one of the 48 2025-Q4 glucosamine shipments, organised by Region → Exporter → Shipment rows. No row is duplicated.
S FOR SUPPLIERS
Jump to any destination country to see exactly who your competitors ship to, what they charge, through which port, and how often.
B FOR BUYERS
Jump to your country to see every Indian glucosamine shipment that arrived in 2025-Q4: supplier, price, dosage, port.
§10.1 Global totals
SHIPMENTS
48
across all regions
TOTAL USD
$692K
2025-Q4 FOB value
UNITS
3.3M
tablets, capsules, etc.
SUPPLIERS
24
Indian exporters
BUYERS
23
global importers
COUNTRIES
21
destinations
§10.2 Regional breakdown
Africa
$78K
11.2%
9 ctry · 14 ships
Asia
$102K
14.7%
5 ctry · 12 ships
Europe
$438K
63.3%
4 ctry · 18 ships
Americas
$75K
10.8%
3 ctry · 4 ships
§10.3 Key insights from the data
🌍
Africa is the largest region at $78K (11.2%), spanning 9 countries.
🏢
24 Indian suppliers shipped to 23 buyers across 21 countries — average shipment value $14K.
📄
Top 0 markets: .
🔍
Every row below is real customs data — date, importer, dosage, brand, quantity, unit price, total USD, origin port, destination port, and transport mode.
All 21 global glucosamine importers — complete list ranked by USD
KEY TAKEAWAYThis directory lists every company that imported Indian glucosamine in 2025-Q4.
S FOR SUPPLIERS
Search for potential customers by country and dosage form.
B FOR BUYERS
Find your company and see which Indian supplier serves you.
#
Buyer
Country
Ships
USD
Primary supplier
Dosage forms
1
MOVI HEALTH LLC
Romania
11
$190K
SAVA HEALTHCARE LTD
Tablet
2
PANBIO PHARM LLC
Russia
3
$100K
PANACEA BIOTEC PHARM…
Capsule
3
PHARMAZEN MEDICALS PTE LTD
Singapore
1
$67K
MEDREICH LTD
Capsule
4
DROGUERIA SAIMED S.A DE C.V
El Salvador
1
$46K
CAPLIN POINT LABORAT…
Tablet
5
LYMENS MEDICAL SUPPLIES LTD
Ghana
1
$29K
THE MADRAS PHARMACEU…
Tablet
6
FUTURA, SOCIEDAD ANONIMA
Guatemala
2
$27K
XL LABORATORIES PVT …
Granules
7
TOO ANADHI
Kazakhstan
1
$18K
OXFORD LABORATORIES …
8
EURIMEX PHARMAPARC DACTIVITES ETRE
France
1
$15K
MEDNEXT BIOTECH LTD
Tablet
9
HEALOL PHARMACEUTICALS SDN BHD
Malaysia
1
$7K
MEDREICH LTD
Tablet
10
ARIA PHRAMA CO LTD
Afghanistan
2
$6K
ANVIS LABORATORIES P…
Tablet
11
NAWI FAQIRI LTD
Afghanistan
2
$4K
ZEE LABORATORIES LTD
Tablet
12
LEGIT MEDIQ 2007 LTD
Kenya
1
$3K
COMED CHEMICALS LTD
Tablet
13
SONIA PHARMACY
Equatorial Guinea
1
$1K
REGAL LABORATORIES
Tablet
14
PROPHARMA S.A
Haiti
1
$1K
AXON DRUGS PVT LTD
Tablet
15
LIFELINE PHARMACEUTICALS OF
Lesotho
2
$699.21
NUMED PHARMA DISTRIB…
Tablet
16
KALKAAL HOSPITAL
Somalia
1
$581.36
CURE EARTH PHARMA
Capsule
17
COCIETE BIKA MULTI ACTIVITIES
Chad
1
$109.81
BAKER & DAVIS PVT LTD
Tablet
18
GKV GLOBAL SERVICES
Malaysia
1
$71.86
GOOD HEALTH PHARMA
Other
19
SEQUENCE MEDICARE SDN BHD
Malaysia
2
$58.65
MERCURY MEDICARE
Tablet
20
BAPA KAZADI
DR Congo
1
$36.86
RUSHI MARKETING
21
GOOD HEALTH (PTY) LTD
Seychelles
1
$1.91
AL-SUPREME EXPORTS
Tablet
This report covers 48 2025-Q4 Glucosamine shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/glucosamine
Talk to our trade analyst
Need a custom glucosamine report or a deeper dive into any market? Our team is ready.